Tango Therapeutics, Inc. (TNGX) stock
TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
Tango Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Tango Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $133.65M, down 2.1% year over year. For fiscal 2025 it was $132.17M, down 8.2% from the year before. The highest annual figure on record is $143.92M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.17M | -8.2% |
| FY2024 | Dec 31, 2024 | $143.92M | +24.9% |
| FY2023 | Dec 31, 2023 | $115.20M | +8.8% |
| FY2022 | Dec 31, 2022 | $105.91M | +36.4% |
| FY2021 | Dec 31, 2021 | $77.64M | +55.3% |
| FY2020 | Dec 31, 2020 | $49.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $37.20M | +13.4% |
| Q1 FY2026 | Mar 31, 2026 | $33.53M | -8.0% |
| Q4 FY2025 | Dec 31, 2025 | $32.10M | -5.4% |
| Q3 FY2025 | Sep 30, 2025 | $30.82M | -7.4% |
| Q2 FY2025 | Jun 30, 2025 | $32.81M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $36.44M | -4.3% |
| Q4 FY2024 | Dec 31, 2024 | $33.94M | +8.3% |
| Q3 FY2024 | Sep 30, 2024 | $33.26M | +22.5% |
| Q2 FY2024 | Jun 30, 2024 | $38.65M | +34.8% |
| Q1 FY2024 | Mar 31, 2024 | $38.07M | +35.8% |
| Q4 FY2023 | Dec 31, 2023 | $31.34M | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $27.15M | -5.5% |
| Q2 FY2023 | Jun 30, 2023 | $28.67M | +20.8% |
| Q1 FY2023 | Mar 31, 2023 | $28.04M | +15.2% |
| Q4 FY2022 | Dec 31, 2022 | $29.09M | +34.5% |
| Q3 FY2022 | Sep 30, 2022 | $28.74M | +31.1% |
| Q2 FY2022 | Jun 30, 2022 | $23.74M | +24.4% |
| Q1 FY2022 | Mar 31, 2022 | $24.33M | +62.2% |
| Q4 FY2021 | Dec 31, 2021 | $21.63M | +43.6% |
| Q3 FY2021 | Sep 30, 2021 | $21.92M | +68.9% |
| Q2 FY2021 | Jun 30, 2021 | $19.08M | – |
| Q1 FY2021 | Mar 31, 2021 | $15.00M | – |
| Q4 FY2020 | Dec 31, 2020 | $15.06M | – |
| Q3 FY2020 | Sep 30, 2020 | $12.98M | – |
See a number that looks wrong?